San Diego-based Genelux Corp.’s Board of Directors has appointed John D. Prunty chief financial officer, effective Feb.10.
Genelux is a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics.
Prior to joining Genelux Corp., Prunty served as senior vice president, chief financial officer and corporate secretary of Optimer Pharmaceuticals, a San Diego-based biotech focused on anti-infective development, from 2006 until mid 2012.
Before his tenure at Optimer, Prunty held several key positions with Maxim Pharmaceuticals Inc., a biopharmaceutical company, from 2000 to 2006, including chief financial officer, vice president of finance, and corporate secretary.
Prunty served as senior director of finance and corporate controller at Gen-Probe Inc. from 1997 to 2000. He also held senior management positions at I-Bus, which was a division of Maxwell Technologies Inc., an electronic device company.
Prunty began his career as an auditor at Ernst & Young LLP where he spent seven years in public accounting. He is a certified public accountant and received a B.B.A. from the University of San Diego and an master’s degree in management from San Diego State University.